[Dermatologic toxicity to sorafenib].
نویسندگان
چکیده
1. Edwards JH, Harnden DG, Cameron AH, Crosse VM, Wolff OH. A new trisomic syndrome. Lancet. 1960;1:787-90. 2. Warkany J, Passarge E, Smith LB. Congenital malformations in autosomal trisomy syndromes. Am J Dis Child. 1966;112:502-17. 3. Rasmussen SA, Wong LY, Yang Q, May KM, Friedman JM. Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics. 2003;111:777-84. 4. Carter PE, Pearn JH, Bell J, Martin N, Anderson NG. Survival in trisomy 18. Life tables for use in genetic counselling and clinical paediatrics. Clin Genet. 1985;27:59-61. 5. Jones KL. Trisomy 18 syndrome. In: Jones KL, ed. Smith’s recognizable patterns of human malformation. Philadelphia: Saunders;1997. p. 16-7. 6. Petek E, Pertl B, Tschernigg M, Bauer M, Mayr J, Wagner K, et al. Characterisation of a 19-year-old “long-term survivor” with Edwards syndrome. Genet Couns. 2003;14:239-44.
منابع مشابه
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
PURPOSE Sorafenib, a vascular endothelial growth factor (VEGF) receptor-2 and RAF kinase inhibitor, commonly causes skin toxicity. We retrospectively analyzed dermatologic toxicity in patients receiving combined antiangiogenic therapy involving sorafenib and bevacizumab. EXPERIMENTAL DESIGN Castration-resistant prostate cancer and metastatic non-small cell lung cancer patients were accrued to...
متن کاملEffects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.
Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC) treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent findings suggest that resistance to sorafenib may have a reversible phenotype. In addition, loss of responsiveness has been proposed to be due to a gradual decrease in sorafenib plasma levels in patients. Here, the possible mechanisms underlyin...
متن کاملThe effect of nanomicelle curcumin, sorafenib, and combination of the two on the cyclin D1 gene expression of the hepatocellular carcinoma cell line (HUH7)
Objective(s): Hepatocellular carcinoma (HCC) is one of the most significant health condition around the world. As the only curative therapies, liver transplantation and surgical resection are the clinical treatments of HCC. Due to the systemic toxicity and severe side effects of these treatments, it is vital to establish new therapeutic approaches. The present study ai...
متن کاملEarly Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
BACKGROUND Identifying predictive biomarkers of drug response is of key importance to improve therapy management and drug selection in cancer therapy. To date, the influence of drug exposure and pharmacogenetic variants on sorafenib-induced toxicity remains poorly documented. The aim of this pharmacokinetic/pharmacodynamic (PK/PD) study was to investigate the relationship between early toxicity...
متن کاملEffects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma. Running title – Sorafenib levels and resistance in HCC
The authors disclose no potential conflicts of interest. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ABSTRACT Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC) treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent findings suggest that resistance to sorafenib may have a reversible phenotyp...
متن کاملDermatologic symptoms associated with the multikinase inhibitor sorafenib.
BACKGROUND The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms. OBJECTIVE We sought to evaluate and provide guidance on the diagnosis and clinical management of dermatologic symptoms associated with sorafenib in patients with advanced solid tumors. METHODS English-language studies representative of a patient population with a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Actas dermo-sifiliograficas
دوره 100 6 شماره
صفحات -
تاریخ انتشار 2009